Platelet-Rich Fraction Reprogramming Adult Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for generating induced pluripotent stem cells from adult cells often involve viral or drug-induced transduction, raising safety concerns and stability issues when transferred to patients.
Innovation Solution
Isolating a population of peripheral blood mononuclear cells and contacting them with a platelet-rich fraction derived from umbilical cord blood or peripheral blood to functionally reprogram adult cells into insulin-producing cells, bypassing the need for viral or drug-induced transduction.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If viral or drug-induced transduction is used to generate induced pluripotent stem cells from adult cells, then reprogramming efficiency is improved, but safety concerns and stability issues arise when transferred to patients
Solution Approach 1:
The invention extracts and eliminates the harmful viral and drug-induced transduction components from the reprogramming process. Instead of using viral vectors or chemical transduction agents, the patent employs a transduction-free approach using small molecules and genetic manipulation that does not require viral delivery systems, thereby removing the source of safety concerns while maintaining reprogramming efficiency
Solution Approach 2:
The invention introduces an intermediary mechanism using small molecules and non-viral genetic manipulation methods to achieve transduction without the harmful effects of viral vectors. This intermediary approach allows for efficient gene delivery and reprogramming while avoiding the integration risks and immunogenicity associated with traditional viral transduction methods
2Adaptability or versatility
If traditional transduction methods are used for stem cell generation, then cell reprogramming capability is achieved, but safety concerns and stability issues prevent clinical application
Solution Approach 1:
The invention converts the potential harm of transduction by using small molecules and non-viral methods that avoid the dangerous integration and immunogenicity effects of viral vectors. The approach transforms the reprogramming process into a safer procedure that maintains effectiveness while eliminating harmful side effects, making clinical application feasible
Solution Approach 2:
The invention employs transient small molecules and non-integrating genetic manipulation methods that do not require permanent viral integration. These temporary, non-persistent reprogramming factors achieve the desired cell conversion without leaving harmful residual effects, allowing the cells to be safely used for therapeutic purposes
Data Source
AI summary
The described invention provides a method of functionally reprogramming adult cells to an immature cell type that expresses one or more embryonic biomarkers with a platelet rich fraction comprising platelet-like cells from umbilical cord blood or peripheral blood, and expanding the immature cell type in vitro under culture conditions to generate an insulin-producing cell population that expresses human beta-cell specific transcription factors and is functionally equivalent to human pancreatic beta-cells. It further provides a pharmaceutical composition comprising a cell product containing a therapeutic amount of an insulin-producing cell population, wherein the insulin-producing cell population expresses human beta-cell specific transcription factors and is functionally equivalent to human pancreatic beta-cells, and a method for treating a recipient subject suffering from a disease characterized by hyperglycemia with the pharmaceutical composition.